METASTATIC BREAST CANCER

This large, late-stage trial is testing if a drug that helps prevent painful bone complications in people with metastatic breast or prostate cancer is just as effective when given every 12 weeks instead of the standard every 4 weeks. The goal is to see if the less frequent schedu…

This early-phase trial is testing a two-part treatment for women whose breast cancer has spread. Doctors take a patient's own immune cells, modify them in a lab to better target cancer, and then infuse them back alongside a drug called pembrolizumab. The main goals are to find a …

This study is testing a drug called Trastuzumab-Deruxtecan (T-DXd) for people with a specific type of advanced breast cancer (HER2-low) that has spread to the brain. The main goal is to see how well the drug shrinks these brain tumors. It will also track side effects and how the …

This study is testing whether adding an immunotherapy drug (pembrolizumab) to a targeted cancer drug (sacituzumab govitecan) works better than the targeted drug alone for people with a specific type of advanced breast cancer that has stopped responding to hormone therapy. About 1…

This early-stage study is testing whether combining an existing breast cancer drug (trastuzumab deruxtecan) with other cancer therapies is safe and effective for patients with advanced HER2-low breast cancer. It involves 138 adults whose cancer has spread and who have tried other…

This study is testing whether adding a pill called niraparib to the standard IV drug trastuzumab is safe and effective for people with advanced HER2-positive breast cancer that has spread. It's for patients whose cancer has grown despite previous HER2-targeted treatments. The mai…

This trial was planned to compare a newer drug (trastuzumab deruxtecan) against standard treatments for a specific type of advanced breast cancer that has spread. It aimed to see which approach was better at controlling the disease and delaying its progression. However, the trial…

This study is testing two different treatment approaches for women with advanced breast cancer that has grown despite prior hormone therapy and chemotherapy. It compares a new drug called abemaciclib taken alone versus abemaciclib combined with the hormone drug tamoxifen. The mai…

This study is testing a new drug, MEN1611, given alone and with a chemotherapy called eribulin, for people with advanced breast cancer that has specific genetic changes. The goal is to see if these treatments can help control the cancer and are safe. It is for patients whose canc…

This study is testing whether adding a highly focused, high-dose radiation treatment to standard care helps people with breast, lung, or prostate cancer that has spread to only a few bones (1-5 sites). It aims to see if this combined approach can keep the cancer from getting wors…

This study compares a new approach using two targeted oral medications against standard chemotherapy for advanced breast cancer that has specific genetic features. After initial chemotherapy, half the participants switch to the targeted drug combination as long-term maintenance t…

This study is testing three different drug combinations for advanced breast cancer that has continued to grow despite prior hormone therapy and a specific type of targeted drug (a CDK4/6 inhibitor). It aims to see if continuing the targeted drug, possibly with an added immunother…

This study is testing an experimental drug called HER3-DXd for patients whose cancer has spread to the brain or the lining of the spinal cord. It is for adults with advanced breast cancer, non-small cell lung cancer, or other solid tumors who have already tried at least one other…

This study aims to better understand and manage high blood sugar, a common side effect of the breast cancer drug alpelisib. Fifteen patients with metastatic breast cancer will wear a continuous glucose monitor (CGM) for at least three months while taking the drug. The goal is to …

This study is testing whether adding a new, experimental drug called onvansertib to a standard chemotherapy (paclitaxel) is safe and effective for people with triple-negative breast cancer that has spread. The first part finds the safest dose, and the second part checks if the co…

This early-stage study is testing the safety of a new cancer vaccine called PVX-410, given alone and with an immunotherapy drug (pembrolizumab), in 20 patients with advanced triple-negative breast cancer. The goal is to see if the combination can safely help the patient's own imm…

This early-stage trial is testing an experimental radioactive drug called RYZ101 for people with advanced ER+ breast cancer that has spread and stopped responding to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors in patients whose ca…

This early-stage study is testing a new drug called ST101 in patients with advanced solid tumors that cannot be surgically removed and have spread. The trial aims to find a safe and effective dose for cancers including glioblastoma, melanoma, breast cancer, and prostate cancer in…

This study is testing whether combining an existing breast cancer drug (trastuzumab deruxtecan) with other cancer medications is safe and effective for people with advanced HER2-positive breast cancer that has spread. Researchers will enroll 245 patients to find the best doses an…

This large, late-stage trial is comparing a new targeted drug called DB-1303 to standard chemotherapy for people with a specific type of advanced breast cancer. The cancer is hormone-positive and has low levels of a protein called HER2, and it has continued to grow despite hormon…

This study is testing whether specific diets or a diabetes medication can prevent dangerous high blood sugar in people receiving a standard two-drug treatment for advanced breast cancer. Researchers want to see if controlling blood sugar helps the cancer therapy work better. The …

This study compares an experimental drug called sacituzumab govitecan against standard chemotherapy options for Asian patients with advanced breast cancer that has spread and stopped responding to at least two prior chemotherapy treatments. The trial aims to see if the new drug c…

This study allows patients with metastatic breast cancer who are already benefiting from ribociclib treatment in previous Novartis trials to continue receiving the medication. The main goal is to monitor long-term safety while providing continued access to the drug. Participants …

This study is testing whether continuing the drug palbociclib, but pairing it with a different hormone therapy called fulvestrant, can help control advanced breast cancer after the cancer has started growing again on a similar initial treatment. It will involve about 60 people wh…

This study is testing whether patients with advanced HER2-positive breast cancer can safely stop their targeted treatment after having their cancer under control for at least three years. The trial involves 82 participants who will either continue treatment or stop it, with resea…

This study is testing if a new drug called RPH-051 works as well as the established drug Perjeta (pertuzumab) for controlling advanced HER2-positive breast cancer. About 246 patients with metastatic or locally advanced cancer will receive either RPH-051 or Perjeta, combined with …

This study is testing whether switching breast cancer treatment earlier, based on a blood test that detects cancer DNA, helps control the disease longer than waiting for standard scans to show it's getting worse. It involves 24 people with advanced, hormone-positive breast cancer…

This study is testing whether a pill called olaparib can help control metastatic breast cancer that has spread in the body. It is for patients whose cancer has a specific weakness—a mutation in certain genes that help repair damaged DNA. The goal is to see if targeting this weakn…

This study is testing if a specific eating pattern can help prevent frailty in older men undergoing hormone therapy for prostate cancer. Researchers will compare a 12-week program of time-restricted eating (eating all meals within a set daily window) to a regular diet. The goal i…

This study aims to measure how much time people with metastatic breast or advanced ovarian cancer spend on treatment-related activities like appointments, travel, medication management, and paperwork. Participants carry a smartphone for 28 days to track their activities and compl…

This study aims to understand how the cancer drug tucatinib reaches brain tumors in patients whose breast cancer has spread to the brain. Researchers will examine tumor tissue from 9 patients who are already scheduled for brain surgery to see how the drug is absorbed and why some…

This study is testing a new type of PET/CT scan to see if it can show how breast cancer tumors respond to a combination of two drugs. Researchers want to see if changes on the scan early in treatment can predict how well the patient will do later. The study involves about 20 peop…

This study analyzes existing medical records from 7,933 patients with advanced breast cancer that has specific genetic changes (HER2-altered). Researchers are looking at what treatments patients actually received in real-world settings and how long they lived after different trea…

This study is observing whether tracking cancer cells circulating in the blood (CTCs) can help doctors make better treatment decisions for people with metastatic breast cancer. It involves 65 patients who will have blood drawn to see if the CTC results match up with their standar…